Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model-Reference-Cited by-同舟云学术

Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model

Published:2019-01-15 Issue:1 Volume:60 Page:245
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Sun Michel M.¹,Chan Ann M.¹,Law Samuel M.¹,Duarte Sergio²,Diaz-Aguilar Daniel¹,Wadehra Madhuri³,Gordon Lynn K.¹

Affiliation:

1. Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States

2. Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States

3. Departments of Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization in vitro and in vivo;Frontiers in Pharmacology;2023-07-11

2. Epithelial membrane protein 2 (EMP2): A systematic review of its implications in pathogenesis;Acta Histochemica;2023-01

3. Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines;Scientific Reports;2022-11-12

4. Dexamethasone and MicroRNA-204 Inhibit Corneal Neovascularization;Military Medicine;2022-08-31

5. Preparation and in vitro and in vivo evaluation of an isoliquiritigenin-loaded ophthalmic nanoemulsion for the treatment of corneal neovascularization;Drug Delivery;2022-07-10